ema glp-1 vision loss recommendation october 2025 A Critical Eye on Receptor Agonists GLP-1 Pipeline Update: May 2025
Description
Improved body composition
In the 2026 survey 73.9% (249/337 [95% CIs 69.0-78.4%]) of patients who are eligible for a GLP-1RA who have not used these a GLP-1RA and have expressed an interest in participating in a clinical trial of a GLP-1RA
The Trump administration announced a pricing model for popular GLP-1 drugs used to treat type 2 diabetes and obesity
Top 5 semaglutide side effects: nausea, diarrhea, indigestion, fatigue, and headache
